United Therapeutics (NASDAQ:UTHR) Given New $400.00 Price Target at TD Cowen

United Therapeutics (NASDAQ:UTHR) had its price objective hoisted by TD Cowen from $350.00 to $400.00 in a report released on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

UTHR has been the topic of a number of other research reports. Oppenheimer increased their price target on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Bank of America cut their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research note on Thursday, August 1st. LADENBURG THALM/SH SH lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Jefferies Financial Group lifted their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $361.33.

United Therapeutics Trading Up 0.6 %

UTHR opened at $370.60 on Monday. The firm has a market cap of $16.49 billion, a P/E ratio of 17.03, a P/E/G ratio of 1.34 and a beta of 0.57. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The stock has a 50-day moving average of $350.66 and a 200 day moving average of $309.00. United Therapeutics has a 12 month low of $208.62 and a 12 month high of $377.03.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. During the same period last year, the company earned $5.24 EPS. The business’s revenue was up 19.8% compared to the same quarter last year. As a group, research analysts forecast that United Therapeutics will post 24.72 EPS for the current year.

Insider Activity at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 7,785 shares of United Therapeutics stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the completion of the sale, the chief financial officer now owns 2,615 shares of the company’s stock, valued at approximately $947,597.55. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $338.61, for a total transaction of $1,218,996.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $44,019.30. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO James Edgemond sold 7,785 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the transaction, the chief financial officer now directly owns 2,615 shares of the company’s stock, valued at approximately $947,597.55. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 102,230 shares of company stock valued at $34,817,406 in the last ninety days. Company insiders own 11.90% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. LSV Asset Management lifted its holdings in United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after acquiring an additional 436,851 shares during the period. Swedbank AB acquired a new position in shares of United Therapeutics in the 1st quarter valued at $97,316,000. Nordea Investment Management AB boosted its holdings in United Therapeutics by 677.6% during the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after buying an additional 262,222 shares in the last quarter. Canada Pension Plan Investment Board grew its position in United Therapeutics by 567.2% during the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock valued at $41,533,000 after buying an additional 153,700 shares during the period. Finally, Pacer Advisors Inc. increased its holdings in United Therapeutics by 19.6% in the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after buying an additional 92,240 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.